Synlogic, Inc. SYBX encountered a loss of $1.71 per share in the fourth quarter, missing the Zacks Consensus Estimate of -$1.11. However, the figures show an improvement from a loss of $3.60 per share reported a year earlier, with adjustments made for non-recurring items.
This unexpected report reflects an earnings surprise of -54.05%. Last quarter, analysts predicted a loss of $2.55 per share, while the actual loss was -$2.57, resulting in a minor surprise of -0.78%.
In the past four quarters, Synlogic has exceeded the consensus EPS estimates twice.
The company, operating in the Zacks Medical – Biomedical and Genetics sector, generated revenues of $2.77 million for the quarter ending December 2023, surpassing the Zacks Consensus Estimate by 2.37%. This figure is significantly higher compared to the $0.11 million in revenues reported a year earlier. Synlogic has managed to surpass consensus revenue estimates on two occasions in the last four quarters.
The company’s stock performance will heavily rely on management’s outlook during the upcoming earnings call, dictating the immediate price movement based on the latest financial figures and future earnings projections.
Since the start of the year, Synlogic shares have plummeted by approximately 50.7%, a stark contrast to the S&P 500’s 8% gain.
Future Speculations for Synlogic, Inc.
Despite its underperformance compared to the market this year, investors are left pondering about Synlogic’s future trajectory. One reliable metric to gauge this is the company’s earnings outlook, which encapsulates current consensus earnings projections for the upcoming quarter(s) and recent changes in these expectations.
Studies have shown a close interconnection between short-term stock movements and variations in earnings estimate revisions. Investors can monitor such alterations or rely on established tools like the Zacks Rank, known for effectively leveraging earnings estimate revisions.
Leading up to this earnings release, Synlogic’s estimate revisions demonstrate a positive trend. Despite the potential changes post the recent earnings report, the current status indicates a Zacks Rank #2 (Buy) for the company, suggesting that the shares are poised to outperform the market shortly.
Looking ahead, evolving estimates for the upcoming quarters and the current fiscal year will be closely watched. Presently, the consensus EPS estimate stands at -$1.38 for the next quarter, with revenues projected at $0.2 million, and -$4.18 EPS for the current fiscal year, with revenues expected to reach $0.79 million.
It’s imperative for investors to consider the industry’s outlook as well, given its potential influence on stock performance. The Medical – Biomedical and Genetics sector presently ranks in the top 36% of the 250-plus Zacks industries. Research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by over a 2 to 1 ratio.
Another player in the same sector, Barinthus Biotherapeutics PLC Sponsored ADR BRNS, is yet to disclose its results for the quarter ending December 2023.
Anticipations are for a $0.55 per share loss in the upcoming report, marking no change from the prior year’s quarter. The consensus EPS estimate has remained stable over the last 30 days.
Barinthus Biotherapeutics PLC Sponsored ADR is expected to post revenues of $0.02 million, a steep 99.7% decline from the same quarter last year.
To delve into further insights, check out the original article on Zacks.com here.